United States · 
What does NovaQuest invest in?
NovaQuest invests most often at Debt and Series A (67% of the rounds on record), in sectors such as Biopharma and Animal Health.
NovaQuest highlights
- 01
1 cheques in the last 12 months
- 02
Mostly Debt and Series A: 67% of its rounds
- 03
Sole investor in 1 rounds, median $50M
- 04
2 exits from the portfolio
What they do
NovaQuest Capital Management promotes the late-stage development of life-saving drugs with its unique global platform, offering Late-stage PRODUCT FINANCE™ investments in global biopharmaceutical products.From their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- BiopharmaAnimal Health
- Based in
- Raleigh, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first10 appearances
- 2025
2 rounds
- Dec
- Jun
- 2024
1 round
- Jul
- 2022
3 rounds
- Nov
- May
- May
- 2018
1 round
- Nov
- 2013
1 round
- Sept
- 2007
2 rounds
- Nov
- Apr
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration24 named
AGAkito Gerald UmedaDirector of the GP LTD.iFiling they signed
APAshton PooleExecutive OfficeriFiling they signed
BEBryan Edwards MillsMember, Chief Administrative Officer, Management Committee MemberiForm ADV
CGCarl Gerald HellmanDirector of the GP LTD.iFiling they signed
CGChris Gerald GordonDirector of the GP LTD.iFiling they signed
DWDevin Weiss HoldenChief Compliance OfficeriForm ADV
EGErnest Gerald BrownDirector of the sole member of the General PartneriFiling they signed
FGFred Gerald CohenDirector of the GP LTD.iFiling they signed
GGGaetano Gerald PetrelliDirector of the GP LTD.iFiling they signed
HEHidekazu E. TanakaDirector of the GP LTD.iFiling they signed
HGHisaharo Gerald KogaDirector of the GP LTD.iFiling they signed
IGIkegami Gerald ManabuDirector of the GP LTD.iFiling they signed
JEJacob E. ComerDirector of the GP LTD.iFiling they signed
JGJames Gerald O'BrienDirector of the General PartneriFiling they signed
JGJeffrey Gerald EdwardsDirector of the GP LTD.iFiling they signed
JGJohn Gerald BradleyDirector of the sole member of the General PartneriFiling they signed
JLJohn L. Bradley, Jr.Director of the sole member of the General PartneriFiling they signed
JEJohnathan E. TunnicliffeDirector of the GP LTD.iFiling they signed
JEJonathan E. TunnicliffeDirector of the GP LTD.iFiling they signed
MGManabu Gerald IkegamiDirector of the sole member of the General PartneriFiling they signed
MGMichael Gerald BolognaMember, Chief Investment Officer, Management Committee MemberiForm ADV
MJMichael J. SorensenOfficer of the GP LTDiFiling they signed
MJMichael J. SorensonOfficer of the GP LTD.iFiling they signed
MGMitsuhiro Gerald GotoDirector of the sole member of the General PartneriFiling they signed
We also hold 62 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$1.5Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Novaquest Capital Management, L.L.C.
- SEC number
- CRD 160359
Funds on its Form ADV
39 private funds, $3.2B in gross assets · filed Oct 2024
- NovaQuest Pharma Opportunities Fund V, L.P.Private equity18 investors$656M
- NovaQuest Pharma Opportunities Fund V (Delaware), L.P.Private equity6 investors$380M
- NovaQuest Co-Investment Fund VIII, L.P.Private equity51 investors$228M
- NovaQuest Pharma Opportunities Fund IV, L.P.Private equity36 investors$181M
- NovaQuest Animal Health Opportunities Fund Aggregator, L.P.Private equity2 investors$132M
- NQ Project Pharaoh, L.P.Private equity20 investors$130M
- NovaQuest Pharma Opportunities Fund IV Aggregator, L.P.Private equity2 investors$118M
- NovaQuest Animal Health Opportunities Fund (Delaware), L.P.Private equity1 investor$117M
- NQP SPV II, L.P.Private equity20 investors$95M
- NovaQuest Pharma Opportunities Fund VI, L.P.Private equity2 investors$88M
And 29 more on the filing.
What they claim to have backed
From their own portfolio page (on their website)
6 of 29 we have independently watched raise
FibroGenGallantNevakarPhathom PharmaceuticalsRoivantTarganAceragenArgentaCalifornia CryobankCerevelCovenantDermavantGrunenthalHansa BiopharmaHospiraLupinMI RNAMesoblastMileutisMundi PharmaMycovia PharmaceuticalsMyovantNewmediacampaignsPfizerRevanceSanofiSebelapharmaShionogiTakeda
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed2 in all
Ambit BiosciencesBought by Daiichi Sankyo$410MSept 2014
PreCision DermatologyBought by Valeant Pharmaceuticals International$500MFeb 2014
An exit counts when it came after the firm's first round in the company. From historical deal records.